Amgen Q4: Good Quarter, Ok Guidance, But MariTide Concerns …

1 day ago · Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. ... Good Quarter, Ok Guidance, But …

CouponFollow Extension

19%
OFF

Amgen Q4: Good Quarter, Ok Guidance, But MariTide Concerns …

2 weeks from now

1 day ago · Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. ... Good Quarter, Ok Guidance, But …

seekingalpha.com

$20
OFF

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

2 weeks from now

2 days ago · The most important numbers for Amgen are in its guidance, Syed said. For the year, Amgen guided to adjusted earnings of $20 to $21.20 per share. The midpoint of the outlook, …

investors.com

11%
OFF

Amgen Profits Rise, Next MariTide Studies Start By Mid-year

2 weeks from now

2 days ago · Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but …

yahoo.com

11%
OFF

Amgen Profits Rise, Next MariTide Studies Start By Mid-year

2 weeks from now

2 days ago · MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - …

reuters.com

20%
OFF

Amgen's Stock Closes Off Lows To Avoid Worst Day In 24

2 weeks from now

Nov 27, 2024 · By Ciara Linnane . Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25% . Amgen Inc.'s stock closed down 4.8% Tuesday, …

morningstar.com

7%
OFF

Amgen Drops 7% After A 'Big, Unknown Risk' Rattles Obesity Shot

2 weeks from now

Nov 12, 2024 · Amgen stock has been on a run this year amid its efforts in weight loss. But shares dropped below the lower boundary of a flat base with a buy point at 346.85 on …

investors.com

$19.60
OFF

Amgen Stock: MariTide's Weight Loss Potential - MarketBeat

2 weeks from now

Aug 7, 2024 · Amgen is placing big bets on MariTide, the weight loss drug in its pipeline. ... This has raised concerns about its effectiveness compared to these drugs. ... of $19.60; however, it …

marketbeat.com

11%
OFF

Amgen Profits Rise, Next MariTide Studies Start By Mid-year

2 weeks from now

2 days ago · Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but …

yahoo.com

FAQs about Amgen Q4: Good Quarter, Ok Guidance, But MariTide Concerns … Coupon?

How did Amgen perform in Q4 2024?

Edmund Ingham Investing Group Leader Follow Play(14min) Summary Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with growth from newer drugs like Repatha, Evenity, and Horizon assets. ...

What are Amgen investors looking for in maritide?

Amgen investors are focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. Amgen on Tuesday said follow-up data from that study, and from a trial of the drug in people with diabetes, are expected in the second half of this year. ...

Why did Amgen make a higher quarterly profit?

By Deena Beasley (Reuters) - Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug. ...

Should you buy Amgen (AMGN) in 2025?

Despite strong performance, Amgen's high debt levels and cautious 2025 guidance lead to a Hold rating, with Novo and Regeneron preferred. JHVEPhoto Investment Overview Amgen (NASDAQ:AMGN), the Thousand Oaks, California based Pharma giant, announced its Q4 and full-year 2024 earnings yesterday, February 4th 2025. Let's look at the key numbers. ...

What if Amgen doesn't develop Mari-tide?

Amgen remains a strong company with 13 "blockbuster" (>$1bn per annum) drugs in its product portfolio, but without Mari-Tide, the outlook for the Pharma looks a little more pedestrian, and the patent expiry issues will be more keenly felt if the star pipeline asset's development stumbles. ...

Is Amgen a good Pharma pick for 2025?

A dividend yield today of 3.3% is another plus point. However, all things considered, I no longer rate Amgen as a top three Pharma pick for 2025 - my choices would be Novo, Regeneron, and A.N. Other - so I am downgrading my rating to a Hold. ...